We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY (XRAY) Acquires Byte to Boost Clear Aligner Business
Read MoreHide Full Article
DENTSPLY SIRONA Inc. (XRAY - Free Report) recently acquired Byte — a fast growing clear aligner company — in an all-cash deal for $1.04 billion. The buyout will not only enable DENTSPLY to boost scale with respect to its SureSmile clear aligner business but also strengthen its connection with dental professionals.
Notably, the deal was funded by cash on DENTSPLY’s balance sheet and completed on Dec 31, 2020.
It is worth mentioning that Byte has maintained its leadership position in the rapidly-growing direct-to-consumer, doctor-directed clear aligner market. The company’s innovative business model, which has been created on doctor-directed care, offers outstanding outcomes for patients with mild to moderate orthodontic needs.
This buyout is likely to provide a boost to DENTSPLY’s Technologies & Equipment segment.
Significance of the Acquisition
The combination of two companies will ensure expansion of patient access to quality care and lend support to the success of the acquirer’s dental partners worldwide. The collective strengths of both the companies will help DENTSPLY to unlock incremental growth, while capitalizing on growing demand for clear aligner solutions.
Notably, the buyout is accretive to DENTSPLY’s revenue growth rate and adjusted earnings per share (EPS) immediately. In fact, with respect to adjusted EPS, the transaction is expected to deliver accretion of 5 cents in 2021 and be incrementally accretive beyond 2021. Moreover, DENTSPLY anticipates combined clear aligner revenue run-rate in excess of $300 million by the end of 2021.
Market Prospects
Per a report by Grand View Research, the global clear aligners market (worth $2.2 billion in 2019) is anticipated to witness a CAGR of 23.1% from 2020 to 2027. Hence, this buyout is a well-timed one for DENTSPLY.
Price Performance
Shares of the Zacks Rank #3 (Hold) company have lost 5.5% in a year’s time against the industry’s growth of 16%.
Merit Medical has a projected long-term earnings growth rate of 12.6%.
Patterson Companies has an estimated long-term earnings growth rate of 9.6%.
IDEXX Laboratories has a projected long-term earnings growth rate of 15.8%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
DENTSPLY (XRAY) Acquires Byte to Boost Clear Aligner Business
DENTSPLY SIRONA Inc. (XRAY - Free Report) recently acquired Byte — a fast growing clear aligner company — in an all-cash deal for $1.04 billion. The buyout will not only enable DENTSPLY to boost scale with respect to its SureSmile clear aligner business but also strengthen its connection with dental professionals.
Notably, the deal was funded by cash on DENTSPLY’s balance sheet and completed on Dec 31, 2020.
It is worth mentioning that Byte has maintained its leadership position in the rapidly-growing direct-to-consumer, doctor-directed clear aligner market. The company’s innovative business model, which has been created on doctor-directed care, offers outstanding outcomes for patients with mild to moderate orthodontic needs.
This buyout is likely to provide a boost to DENTSPLY’s Technologies & Equipment segment.
Significance of the Acquisition
The combination of two companies will ensure expansion of patient access to quality care and lend support to the success of the acquirer’s dental partners worldwide. The collective strengths of both the companies will help DENTSPLY to unlock incremental growth, while capitalizing on growing demand for clear aligner solutions.
Notably, the buyout is accretive to DENTSPLY’s revenue growth rate and adjusted earnings per share (EPS) immediately. In fact, with respect to adjusted EPS, the transaction is expected to deliver accretion of 5 cents in 2021 and be incrementally accretive beyond 2021. Moreover, DENTSPLY anticipates combined clear aligner revenue run-rate in excess of $300 million by the end of 2021.
Market Prospects
Per a report by Grand View Research, the global clear aligners market (worth $2.2 billion in 2019) is anticipated to witness a CAGR of 23.1% from 2020 to 2027. Hence, this buyout is a well-timed one for DENTSPLY.
Price Performance
Shares of the Zacks Rank #3 (Hold) company have lost 5.5% in a year’s time against the industry’s growth of 16%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Merit Medical Systems, Inc. (MMSI - Free Report) , Patterson Companies, Inc. (PDCO - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merit Medical has a projected long-term earnings growth rate of 12.6%.
Patterson Companies has an estimated long-term earnings growth rate of 9.6%.
IDEXX Laboratories has a projected long-term earnings growth rate of 15.8%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>